Clinical Research On Zhike Pingchuan Soft Capsule In The Treatment Of Acute Exacerbation Of Chronic Bronchitis And The Impact On Serum IL-6

Objective:To observe the Zhike Pingchuan Soft Capsule in the treatment of acute exacerbation of chronic bronchitis (Lung Phlegm-Turbidity and Kidney Deficiency Syndrome) in patients with symptoms of improvement and the impact on serum IL-6,an objective evaluation of its clinical effect.Methods:Selected acute exacerbation of chronic bronchitis (Lung Phlegm-Turbidity and Kidney Deficiency Syndrome) 78 cases of patients, then use the method of randomized, double-blind, placebo and parallel Control, divided into three groups:high dosage group, middle dosage group and control group, and 26 cases in each group. The high dosage group and the middle dosage group were given Zhike Pingchuan Soft Capsule in different dose, while the control group was given the simulator of Zhike Pingchuan Soft capsule in treatment. Before and after the treatment; patients were observed with symptoms of improvement and serum IL-6 levels.Results:1.Zhike Pingchuan Soft Capsule in the treatment of acute exacerbation of chronic bronchitis is significant in clinical effect. The total effective rate was 92.31% in the high dosage group,88.46% in the middle dosage group,23.07% in the control group; the control rate was 80.77% in the high dosage group,73.08% in the middle dosage group,7.69% in the control group. By comparison, the total effective rate and the control rate both in the high dosage group and the middle dosage group were better than the control group (P<0.05), and the difference between the high dosage group and the middle dosage group was insignificant (P>0.05).2. Zhike Pingchuan Soft Capsule can significantly alleviate the symptoms of cough, expectoration and so on in acute exacerbation of chronic bronchitis. Cough onset time was for 3.45±1.65 days in the high dosage group, 3.36±1.48 days in the middle dosage group,4.13=1.87 days in the control group;cough cure time was for 5.33±1.11 days in the high dosage group,5.48±1.02 days in the middle dosage group,6.20±0.84 days in the control group. By comparison,the high dosage group and the middle dosage group were more effective in alleviating cough onset time and cough cure time than the control group(P<0.05). The difference between the high dosage group and the middle dosage group was insignificant (P>0.05).3. Zhike Pingchuan Soft Capsule can reduce the acute exacerbation of chronic bronchitis in patients with IL-8 levels significantly lower than before treatment, the difference was significant (P>0.05).Conclusion:1. Zhike Pingchuan Soft Capsule can be effective in improving acute exacerbation of chronic bronchitis in patients with symptoms.2. Zhike Pingchuan Soft Capsule can reduce the acute exacerbation of chronic bronchitis in patients with IL-6 levels.3. Zhike Pingchuan Soft Capsule has a significant clinical effect with no adverse reactions.